Nanoconjugated NAP as a Potent and Periphery Selective Mu Opioid Receptor Modulator To Treat Opioid-Induced Constipation
journal contributionposted on 21.11.2016, 00:00 by Guoyan G. Xu, Olga Yu. Zolotarskaya, Dwight A. Williams, Yunyun Yuan, Dana E. Selley, William L. Dewey, Hamid I. Akbarali, Hu Yang, Yan Zhang
Opioids are the mainstay for cancer and noncancer pain management. However, their use is often associated with multiple adverse effects. Among them, the most common and persistent one is probably opioid-induced constipation (OIC). Periphery selective opioid antagonists may alleviate the symptoms of OIC without compromising the analgesic effects of opioids. Recently our laboratories have identified one novel lead compound, 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4′-pyridyl)acetamido]morphinan (NAP), as a peripherally selective mu opioid receptor ligand carrying subnanomolar affinity to the mu opioid receptor and over 100-folds of selectivity over both the delta and kappa opioid receptors, with reasonable oral availability and half-life, and potential to treat OIC. Nanoparticle-based drug delivery systems are now widely considered due to their technological advantages such as good stability, high carrier capacity, low therapeutic side effects, etc. Herein we report nanoparticle supported NAP as a potential candidate for OIC treatment with improved peripheral selectivity over the original lead compound NAP.
Read the peer-reviewed publication
carrier capacityselectivityMu Opioid Receptor ModulatorPeripherykappa opioid receptorsNanoparticle-based drug delivery systemssubnanomolar affinityreport nanoparticleNanoconjugated NAPnoncancer pain managementOpioid-Induced Constipation OpioidsOIC treatmentopioid antagonistsopioid-induced constipationmu opioid receptor ligand100- foldsmu opioid receptorside effectscompound NAP